- Home
- SLGL vs KZIA Comparison
SLGL vs KZIA Comparison
Compare SLGL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- KZIA
- Stock Information
- Founded
- SLGL 1997
- KZIA 1994
- Country
- SLGL Israel
- KZIA Australia
- Employees
- SLGL N/A
- KZIA N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- KZIA Health Care
- Exchange
- SLGL Nasdaq
- KZIA Nasdaq
- Market Cap
- SLGL 18.3M
- KZIA 18.7M
- IPO Year
- SLGL 2018
- KZIA 1999
- Fundamental
- Price
- SLGL $0.52
- KZIA $5.82
- Analyst Decision
- SLGL Strong Buy
- KZIA Strong Buy
- Analyst Count
- SLGL 2
- KZIA 1
- Target Price
- SLGL $5.00
- KZIA $20.00
- AVG Volume (30 Days)
- SLGL 68.5K
- KZIA 123.2K
- Earning Date
- SLGL 11-15-2024
- KZIA 11-29-2024
- Dividend Yield
- SLGL N/A
- KZIA N/A
- EPS Growth
- SLGL N/A
- KZIA N/A
- EPS
- SLGL N/A
- KZIA N/A
- Revenue
- SLGL $11,707,000.00
- KZIA $1,663,331.00
- Revenue This Year
- SLGL $457.85
- KZIA $802.53
- Revenue Next Year
- SLGL N/A
- KZIA N/A
- P/E Ratio
- SLGL N/A
- KZIA N/A
- Revenue Growth
- SLGL 869.93
- KZIA 10739.13
- 52 Week Low
- SLGL $0.33
- KZIA $1.90
- 52 Week High
- SLGL $1.58
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- SLGL 37.57
- KZIA 52.56
- Support Level
- SLGL $0.40
- KZIA $5.37
- Resistance Level
- SLGL $0.57
- KZIA $6.01
- Average True Range (ATR)
- SLGL 0.06
- KZIA 0.73
- MACD
- SLGL -0.01
- KZIA -0.10
- Stochastic Oscillator
- SLGL 36.50
- KZIA 45.55
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.